IRB #

IRB00008243

Title

CRAD001T2302: A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin - RADIANT-4

Principal Investigator

Rodney Pommier

Study Purpose

To learn if everolimus is safe and effective for subjects who have advanced Neuroendocrine tumor (NET) of gastrointestinal (GI) or lung origin.

Medical Condition(s)

Advanced NET of GI or lung origin

Eligibility Criteria

1. Male or female aged 18 or older
2. Confirmed neuroendocrine tumor of GI or lung origin.
3. No history of and no active symptoms related to carcinoid syndrome.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

You will continue to take the study drug as long as you benefit from it, until you experience intolerable side effects, or until you withdraw your consent.

Minors Included

No

Contact

Caron Campbell, RN
503-494-8699

Sponsor

Novartis

Recruitment End

12/31/2013

Compensation Provided

No